Ruxolitinib (Jakavi)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses ruxolitinib (Jakavi), tablet 5 mg, 10 mg, 15 mg, 20 mg, oral.
• Indication: The treatment of steroid-refractory (SR) or dependent acute graft-versus-host disease (aGvHD) in adults and children 12 years and older.